Genocea Biosciences (NASDAQ:GNCA) versus Cardiol Therapeutics (NASDAQ:CRDL) Head-To-Head Review

Cardiol Therapeutics (NASDAQ:CRDL) and Genocea Biosciences (NASDAQ:GNCA) are both small-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their valuation, earnings, profitability, dividends, risk, institutional ownership and analyst recommendations.

Analyst Recommendations

This is a breakdown of recent ratings for Cardiol Therapeutics and Genocea Biosciences, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Cardiol Therapeutics	0	0	5	2	3.29
Genocea Biosciences	0	0	0	0	0.00

Cardiol Therapeutics currently has a consensus target price of $8.40, indicating a potential upside of 731.68%. Given Cardiol Therapeutics’ stronger consensus rating and higher possible upside, equities analysts plainly believe Cardiol Therapeutics is more favorable than Genocea Biosciences.

Profitability

This table compares Cardiol Therapeutics and Genocea Biosciences’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Cardiol Therapeutics	N/A	-194.40%	-129.07%
Genocea Biosciences	N/A	-182.88%	-62.76%

Institutional & Insider Ownership

12.5% of Cardiol Therapeutics shares are held by institutional investors. Comparatively, 0.6% of Genocea Biosciences shares are held by institutional investors. 5.3% of Cardiol Therapeutics shares are held by company insiders. Comparatively, 1.6% of Genocea Biosciences shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Valuation and Earnings

This table compares Cardiol Therapeutics and Genocea Biosciences”s gross revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Cardiol Therapeutics	N/A	N/A	-$20.84 million	($0.37)	-2.73
Genocea Biosciences	$1.91 million	0.00	-$33.20 million	($0.61)	N/A

Cardiol Therapeutics has higher earnings, but lower revenue than Genocea Biosciences. Cardiol Therapeutics is trading at a lower price-to-earnings ratio than Genocea Biosciences, indicating that it is currently the more affordable of the two stocks.

Risk and Volatility

Cardiol Therapeutics has a beta of 1, meaning that its share price has a similar volatility profile to the S&P 500.Comparatively, Genocea Biosciences has a beta of 1.61, meaning that its share price is 61% more volatile than the S&P 500.

Summary

Cardiol Therapeutics beats Genocea Biosciences on 8 of the 13 factors compared between the two stocks.

About Cardiol Therapeutics

Cardiol Therapeutics Inc., a clinical-stage life sciences company, focuses on the research and development of anti-fibrotic and anti-inflammatory therapies for the treatment of heart diseases. Its lead product CardiolRx, which is in Phase II multi-national, randomized, double-blind, and placebo-controlled study to evaluate the efficacy and safety of CardiolRx in acute myocarditis, as well as for the treatment of recurrent pericarditis. The company is also developing CRD-38 injection for subcutaneous administration that is in preclinical development for the treatment of heart failure. It has a license agreement with Meros. The company was incorporated in 2017 and is headquartered in Oakville, Canada.

About Genocea Biosciences

Genocea Biosciences, Inc., a biopharmaceutical company, discovers and develops novel cancer immunotherapies. The company uses its proprietary discovery platform, ATLAS, which profiles each patient's CD4+ and CD8+ T cell immune responses to every target or antigen identified by next-generation sequencing of that patient's tumor. Its products include GEN-011, an adoptive T cell therapy, which is in Phase 1/2a clinical trials for the treatment of solid tumors; and GEN-009, a neoantigen vaccine candidate, which is in Phase 1/2a clinical trials that delivers adjuvanted synthetic long peptides spanning ATLAS-identified anti-tumor neoantigens. The company was incorporated in 2006 and is based in Cambridge, Massachusetts. On July 5, 2022, Genocea Biosciences, Inc. filed a voluntary petition for reorganization under Chapter 11 in the U.S. Bankruptcy Court for the District of Massachusetts.